Whole Foods implements sustainable packaging guidelines
This article was originally published in The Rose Sheet
Executive Summary
More than 2,100 body-care and supplement suppliers have updated their packaging to meet new Whole Foods "green" mandates, firm announces Sept. 8. All new body-care and supplement suppliers will need to adhere to the new packaging guidelines before their products can be sold on store shelves, firm says. Grocer announced in September 2009 that suppliers would have one year to reduce plastic in product packaging, switch to glass when possible, use recycled packaging materials when appropriate and feature the highest percentage of post-consumer recycled (PCR) content available. Whole Foods' expects its own Whole Body line of personal-care products to be packaged in 100% PCR by late 2010. "At Whole Foods Market, we're committed to reducing, reusing and recycling waste on all levels of business, and we're thrilled to be leading the green packaging charge with our store-brand products," Jeremiah McElwee, global Whole Body coordinator for Whole Foods Market says. In June of this year, McElwee announced in a letter to vendors that come June 1, 2011, personal-care products carrying the word "organic" on their labels must be certified under either the National Organic Program or "NSF/ANSI 305" to be carried by Whole Foods stores (1"The Rose Sheet" June 14, 2010)
You may also be interested in...
Whole Foods Stretching Brands' Resources With New Progressive Policies
Whole Foods Market's heightening expectations for the natural and organic brands it carries have manufacturers assessing how to foot the bill and could bump some from store shelves altogether
New Whole Foods Policy Requires USDA Certification For Organic Body Care
Come June 1, 2011, personal-care products flashing the word "organic" on their labels must be certified under either the National Organic Program or "NSF/ANSI 305" to be carried by Whole Foods stores, according to the natural retailer's new policy
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.